A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

<p>Abstract</p> <p>Background</p> <p>On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with S-1 plus cis...

Full description

Bibliographic Details
Main Authors: Tsuburaya Akira, Morita Satoshi, Kodera Yasuhiro, Kobayashi Michiya, Shitara Kohei, Yamaguchi Kensei, Yoshikawa Takaki, Yoshida Kazuhiro, Yoshino Shigefumi, Sakamoto Jun-ichi
Format: Article
Language:English
Published: BMC 2012-07-01
Series:BMC Cancer
Subjects:
Biomarker
Capecitabine
Cisplatin
Clinical trial
Gastric cancer
S-1
Online Access:http://www.biomedcentral.com/1471-2407/12/307

Internet

http://www.biomedcentral.com/1471-2407/12/307

Similar Items